| Literature DB >> 15530678 |
Brigitte Cheuvart1, Margaret Burgess, Fred Zepp, Jussi Mertsola, Joanne Wolter, Lode Schuerman.
Abstract
The reduced antigen content diphtheria, tetanus and pertussis (dTpa) vaccine (Boostrixtrade mark) has been shown to induce a strong booster response to all the vaccine components in 4-6 year olds. However, anti-diphtheria antibody levels were observed to be lower when compared to the "full strength" paediatric DTPa vaccine. To assess the impact of this difference on long-term protection, a mathematical model was developed to predict diphtheria antibody decay over time. The model was based on a linear decrease in log-transformed antibody concentrations after the first year post-vaccination. When applied to data collected 3.5 years after vaccination of 4-6 year olds with either DTPa or dTpa, the model predicted that 10 years post-vaccination, 98.6% of subjects vaccinated with dTpa were likely to remain seroprotected against diphtheria, compared to 99.6% vaccinated with DTPa. Therefore, the difference observed in diphtheria antibody geometric mean concentrations 1 month after booster vaccination at 4-6 years with dTpa or DTPa is unlikely to be of clinical relevance 10 years later at the time of the adolescent booster.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15530678 DOI: 10.1016/j.vaccine.2004.06.012
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641